Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

V-902

Supelco

Vardenafil dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H32N6O4S·2HCl
Número de CAS:
224785-90-4
Peso molecular:
561.52
EC Number:
200-659-6
MDL number:
MFCD04972607
UNSPSC Code:
41116107
PubChem Substance ID:
329830239
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

O=C(C1=C(C)N=C(CCC)N1N2)N=C2C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC.Cl.Cl

InChI

1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H

InChI key

NOIHTGOGFDFCBN-UHFFFAOYSA-N

Gene Information

human ... PDE5A(8654)

General description

Vardenafil, a phosphodiesterase inhibitor, is used to treat erectile dysfunction. This Snap-N-Spike® reference solution is applicable for use in urine drug testing, clinical toxicology or forensic analysis by LC-MS/MS or GC/MS. Vardenafil is sold under the trade names Levitra® and Staxyn®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Levitra is a registered trademark of Bayer Aktiengesellschaft
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Staxyn is a registered trademark of Bayer Aktiengesellschaft

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 2

1 of 2

Sildenafil Citrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1807

Sildenafil Citrate

Sildenafil citrate European Pharmacopoeia (EP) Reference Standard

Y0001578

Sildenafil citrate

Daniel J Mans et al.
Journal of pharmaceutical and biomedical analysis, 75, 153-157 (2012-12-25)
Ion mobility spectrometry was used as a rapid screening tool for the detection of acetildenafils, sildenafils and avanafil within adulterated herbal supplement matrices. Acetildenafils show a tendency for partial fragmentation during the desorption/ionization process affording two peaks in the ion
Kenneth Beer
Journal of drugs in dermatology : JDD, 11(12), 1494-1495 (2013-02-05)
Eruptions from drugs are among the most frequently reported adverse events. The most frequent etiologic agents include antibiotics and nonsteroidal anti-inflammatory agents. These eruptions are also a frequent source of visits to dermatology of!ces. Many of the inciting agents are
S I Gamidov et al.
Urologiia (Moscow, Russia : 1999), (3)(3), 102-104 (2013-08-31)
Due to high efficiency, prompt action and low incidence of side effects, phosphodiesterase type 5 inhibitors are the drugs of first choice in the treatment of erectile dysfunction (ED). One of the most widely used drugs in this group currently
[New Levitra in the treatment of erectile dysfunction].
A L Vertkin et al.
Urologiia (Moscow, Russia : 1999), (6)(6), 100-102 (2013-02-06)
Christoph Zenzmaier et al.
Endocrinology, 153(11), 5546-5555 (2012-09-06)
Phosphodiesterase type 5 (PDE5) inhibitors have been demonstrated to improve lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Because BPH is primarily driven by fibroblast-to-myofibroblast trans-differentiation, this study aimed to evaluate the potential of the PDE5 inhibitor vardenafil
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico